Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Stocks were climbing on Thursday led by semiconductors and AI-related names. Taiwan Semiconductor rallied more than 5% after reporting strong fourth quarter results and forecasting higher captial spending. That strength in TSMC was lifting the chip group: Club name Nvidia and Micron were each up 3%, and portfolio holding Broadcom was up 1.5%. Financials were also getting a boost. Goldman Sachs rose 5% after beating fourth quarter earnings, though revenue came in light due to a one-time impact from the transfer of Apple Card to JPMorgan . Fellow Club name BlackRock surged 6% on its fourth quarter beat, highlighting strong base fee growth. The market entered Thursday in overbought territory, according to the S & P Short Range Oscillator , and we raised cash into strength by trimming our Dover position. Eli Lilly shares dropped 5% on a Reuters report that the Federal Drug Administration extended review deadlines on several drugs, including Lilly’s orforglipron — its experimental, once-daily GLP-1 pill to treat type two diabetes and obesity. The GLP-1 market has been driven by injectables, but the obesity pill category is expected to accelerate the category, given patients’ preference for pills. FDA approval of orforglipron would likely be a major catalyst for Club stock Eli Lilly , especially after rival Novo Nordisk jumped on becoming the first to secure FDA approval for a GLP-1 weight-loss pill. We continue to view approval for Lilly as a
